

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
29 January 2004 (29.01.2004)

PCT


(10) International Publication Number  
**WO 2004/009026 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K**
- (21) International Application Number:  
PCT/US2003/022746
- (22) International Filing Date: 22 July 2003 (22.07.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/397,123 22 July 2002 (22.07.2002) US
- (71) Applicant (for all designated States except US): **DUKE UNIVERSITY** [US/US]; c/o Office of Science and Technology, M454 Davison Building, Duke University Medical Center, Durham, NC 27710 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **HELLER, James,**
- H.** [US/US]; 2427 Tilghman Circle, Chapel Hill, NC 27514 (US). **KISHNANI, Priya** [IN/US]; 6 Vinson, Place, Durham, NC 27705 (US). **WORLEY, Gordon** [US/US]; 408 Deming Road, Chaple Hill, NC 27514 (US).
- (74) Agent: **KAGAN, Sarah, A.; BANNER & WITCOFF, LTD.**, 11th floor, 1001 G Street, NW, Washington, D. C. 20001.4597 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: **CHOLINERGIC THERAPY FOR INDIVIDUALS WITH LEARNING DISABILITIES**

Effect of Donepezil Therapy on  
Language Performance in Down syndrome  
Adults with High and Low Language Levels



(57) **Abstract:**— Cholinergic agents are used to improve specific learning deficits and language function in individuals of normal intelligence. Psychosocial deficits including a pragmatics impairment, reading deficits, a problem solving impairment, an information processing impairment, an adaptive function impairment, social skills impairment, attention impairment, a mood impairment and employment skills impairment, can also be treated in this manner. The cholinergic treatments can be combined with more traditional educational, psychological, and behavioral therapies for enhanced therapeutic benefit.



European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

- *without international search report and to be republished upon receipt of that report*